

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

2727-144

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/913361

INTERNATIONAL APPLICATION NO.

PCT/EP00/01877

INTERNATIONAL FILING DATE

06 March 2000 (06.03.00)

PRIORITY DATE CLAIMED

09 March 1999 (06.03.99)

TITLE OF INVENTION

"Method to Detect Male Antifertility Problems"

APPLICANT(S) FOR DO/EO/US

Leopold Flohe, Fulvio Ursini, Antonella Roveri

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

Declaration (unsigned)

WIPO cover page

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/913361	INTERNATIONAL APPLICATION NO. PCT/EP00/01877	ATTORNEY'S DOCKET NUMBER 2727-144
--	--	---

21. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$970.00	
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$840.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$690.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$670.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)				\$96.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	8 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$78.00	\$0.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$860.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input checked="" type="checkbox"/>				\$430.00	
SUBTOTAL =				\$430.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$430.00	
				Amount to be refunded	\$
				charged	\$


- ☒ A check in the amount of **\$430.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **501145** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ronald R. Santucci
Pitney, Hardin, Kipp & Szuch, LLP
711 Third Avenue, 20th Floor
New York, New York 10017

(212)687-6000



SIGNATURE

Ronald R. Santucci

NAME

28,988

REGISTRATION NUMBER

August 13, 2001

DATE

09/913361

518 Rec'd PCT/PTO 13 AUG 2001

2727-144

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Leopold Flohé, Fulvio Ursini and
Antonella Roveri

Serial No.: Not Yet Assigned

International Appln. No.: PCT/EP00/01877

International Filing Date: 06 March 2000

Priority Date Claimed: 09 March 1999

For: METHOD TO DETECT MALE ANTIFERTILITY PROBLEMS

PRELIMINARY AMENDMENT

Box PCT
Commissioner for Patents
Washington, D.C. 20231
Attn: DO/EO/US

S I R:

Preliminary to examination of the above-identified
application kindly amend the application as follows:

In the Specification:

Please rewrite the second paragraph beginning on page 1,
line 20 and continuing to page 3, line 6 as follows:

Selenium is essential for male fertility. In mature
mammalian spermatozoa it is largely restricted to the midpiece
harbouring the helix of mitochondria embedded into a keratine-
like selenium-enriched matrix called the mitochondrial capsule.
Selenium deficiency is associated with impaired sperm motility,
structural alterations of the midpiece up to breakages, and loss

768854A01081301

Express Mail #EL905037055us

of flagellum. The predominant selenoprotein of the mammalian male reproductive system, phospholipid hydroperoxide glutathione peroxidase (PHGPx), was shown to be preferentially expressed in round spermatids but was hardly detectable in terms of messenger RNA or activity in spermatozoa. The basis of the invention is the discovery that PHGPx persists in spermatozoa but as insoluble, enzymatically inactive material forming the mitochondrial capsule. PHGPx activity of this material can be restored by high concentrations of thiols. PHGPx, thus, acts as a peroxidase in the proliferating germ epithelium to prevent oxidative damage. In the late stages of sperm maturation it is oxidatively cross-linked to become a structural element indispensable for sperm function. Accordingly, the determination of the PHGPx content in sperm or any other tissue of humans or livestock can be used to estimate the fertilization potential of sperm.

Please rewrite the third full paragraph on page 3, line 11 as follows:

The sperm sample is, for example, from humans or livestock.

In the Claims:

Kindly rewrite claims 4, 5, 6, 7 and 8 as follows:

4. (Amended) Method according to claim 1, wherein instead of determining enzymatic activity of re-activated latent PHGPx the content of solubilized PHGPx is determined by conventional immunological techniques or measurement of enzymatic activity.
5. (Amended) Method according to claim 1, wherein the chaotropic agent is 4 - 8 M guanidine chloride, 4 - 8 M guanidine thiocyanate or 5 - 8 M urea.
6. (Amended) Method according to claim 1, wherein the thiol is 50 - 300 mM 2-mercaptoethanol, 25 - 300 mM dithiothreitol (DTT) or dithioerythritol (DTE).
7. (Amended) Method according to claim 1, wherein the sperm sample is from humans or livestock.
8. (Amended) Use of a method of claim 1 in a method for predicting the fertilizing potential of spermatozoa in sperm samples.

REMARKS

The claims of the above-identified application have been amended to remove all multiple dependencies. Certain typographical errors were also corrected in the claims and the specification. No new matter has been added. Accordingly, an early examination of the application is respectfully requested.

Applicants wish to note that small entity status may be claimed for this application.

Respectfully submitted,



Ronald R. Santucci
Registration No. 28,988

Pitney, Hardin, Kipp & Szuch, LLP
711 Third Avenue, 20th Floor
New York, New York 10017
212-687-6000

APPENDIX:

In the specification, the second paragraph beginning on page 1, line 20 and continuing to page 3, line 6:

Selenium is essential for male fertility. In mature mammalian spermatozoa it is largely restricted to the midpiece harbouring the helix of mitochondria embedded into a keratine-like selenium-enriched matrix called the mitochondrial capsule. Selenium deficiency is associated with impaired sperm motility, structural alterations of the midpiece up to breakages, and loss of flagellum. The predominant selenoprotein of the mammalian male reproductive system, phospholipid hydroperoxide glutathione peroxidase (PHGPx), was shown to be preferentially expressed in round spermatids but was hardly detectable in terms of messenger RNA or activity in spermatozoa. The basis of the invention is the discovery that PHGPx persists in spermatozoa but as insoluble, enzymatically inactive material forming the mitochondrial capsule. PHGPx activity of this material can be restored by high concentrations of thiols. PHGPx, thus, acts as a peroxidase in the proliferating germ epithelium to prevent oxidative damage. In the late stages of sperm maturation it is oxidatively cross-linked to become a structural element indispensable for sperm function. Accordingly, the determination of the PHGPx content in sperm or any other tissue

of humans or [life stock] livestock can be used to estimate the fertilization potential of sperm.

In the specification, the third full paragraph on page 3, line 11:

The sperm sample is, for example, from humans or [life stock] livestock.

APPENDIX: (cont.)

4. (Amended) Method according to [any of the preceeding claims] claim 1, wherein instead of determining enzymatic activity of re-activated latent PHGPx the content of solubilized PHGPx is determined by conventional immunological techniques or measurement of enzymatic activity.

5. (Amended) Method according to [any of the preceeding claims] claim 1, wherein the chaotropic agent is 4 - 8 M guanidine chloride, 4 - 8 M guanidine thiocyanate or 5 - 8 M urea.

6. (Amended) Method according to [any of the preceeding claims] claim 1, wherein the thiol is 50 - 300 mM 2-mercaptoethanol, 25 - 300 mM dithiothreitol (DTT) or dithioerythritol (DTE).

7. (Amended) Method according to [any of the preceeding claims] claim 1, wherein the sperm sample is from humans or [life stock] livestock.

8. (Amended) Use of a method of [any of the preceeding claims] claim 1 in a method for predicting the fertilizing potential of spermatozoa in sperm samples.

5

10630
Neue internationale Patentanmeldung
auf Basis von EP 99 103 959.5
Anmelder: Prof. Dr. Leopold Flohé

10

Method to detect male antifertility problems

15

The invention relates to a method to detect male antifertility problems based on the determination of latent phospholipid hydroperoxide glutathione peroxidase (PHGPx).

20

Selenium is essential for male fertility. In mature mammalian spermatozoa it is largely restricted to the midpiece harbouring the helix of mitochondria embedded into a keratine-like selenium-enriched matrix called the mitochondrial capsule. Selenium deficiency is associated with impaired sperm motility,

25

structural alterations of the midpiece up to breakages, and loss of *flagellum*. The predominant selenoprotein of the mammalian male reproductive system, phospholipid hydroperoxide glutathione peroxidase (PHGPx), was shown to be preferentially expressed in round spermatids but was hardly detect-

30

able in terms of messenger RNA or activity in spermatozoa. The basis of the invention is the discovery that PHGPx persists in spermatozoa but as insoluble, enzymatically inactive material forming the mitochondrial capsule. PHGPx activity of this material can be restored by high concentrations of thiols. PHGPx, thus, acts as a peroxidase in the proliferating

35

germ epithelium to prevent oxidative damage. In the late stages of sperm maturation it is oxidatively cross-linked to become a structural element indispensable for sperm function. Accordingly, the determination of the PHGPx content in sperm or any other tissue of humans or life stock can be used to estimate the fertilization potential of sperm.

The invention thus in accordance with claim 1 provides a method for the determination of latent phospholipid hydroperoxide glutathione peroxidase (PHGPx) comprising the steps of

- a) obtaining a sperm sample,
- b) solubilizing the spermatozoa by using detergents and chaotropic agents and reactivating latent PHGPx by using high concentrations of thiols and
- c) determining enzymatic activity of reactivated latent PHGPx.

In a further aspect the invention relates to the use of the inventive method in a method for predicting the fertilizing potential of spermatozoa in sperm samples.

Further advantageous and/or preferred embodiments of the invention are subject-matter of the subclaims.

In a preferred embodiment of the inventive method an additional step of removing any reactivating reagents by, e.g., gel filtration is provided between the step of solubilizing the spermatozoa and the step of determining the enzymatic activity of reactivated latent PHGPx.

In a further embodiment of the invention instead of determining enzymatic activity of reactivated latent PHGPx the con-

tent of solubilized PHGPx is determined by conventional immunological techniques or measurement of enzymatic activity.

The used chaotropic agent is, for example, 4 - 8 M guanidine chloride, 4 - 8 M guanidine thiocyanate or 5 - 8 M urea.

The used thiol is, for example, 50 - 300 mM 2-mercaptoethanol, 25 - 300 mM dithiothreitol (DTT) or dithioerythritol (DTE).

The sperm sample is, for example, from humans or life stock.

In the following the invention is disclosed in more detail with reference to examples and to drawings. However, the described specific forms or preferred embodiments are to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the following description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Regarding the cited literature a reference list with more detailed bibliographic information can be found at the end of this specification.

Routine preparations of rat sperm mitochondrial capsules (1) yielded a fraction which was insoluble in 1% SDS and 0.2 mM DTT and displayed expected vesicular appearance in electron microscopy (Fig. 1 a). The vesicles readily disintegrated upon exposure to 0.1 M mercaptoethanol (Fig. 1 b) and became fully soluble in 6 M guanidine-HCL. When the solubilized cap-

sule material was subjected to gel electrophoresis essentially four bands in the 20 kDa region were detected (Fig. 1 c, left lane). Western blotting revealed that the most prominent one reacted with antibodies directed against PHGPx (Fig. 1 c, right lane) which is undetectable as active peroxidase in mature spermatozoa (Tab. 1). Also, N-terminal sequencing of the 21 kDa band representing about 46% of total protein content according to Coomassie stain revealed that it consisted of at least 95% pure PHGPx. Puzzled by this unexpected finding, we investigated the composition of the mitochondrial capsules in more detail by 2D-electrophoresis (Fig. 2 a) followed by microsequencing and/or MALDI-TOF for identification (Fig. 2 b). For this purpose the capsules were dissolved completely in a buffer designed for electrophoretic separation of membrane proteins (see Methods). The spot migrating with an apparent molecular weight of about 21 kDa and focussing at a pH near 8 (spot 3) proved to be PHGPx according to the masses of tryptic peptides detected by MALDI-TOF (Fig. 2 b). By the same technique, also the slightly more acidic charge isomer (spot 4), the more basic ones (spots 1, 2 and 5) as well as the spots 6 and 7 exhibiting a smaller apparent molecular mass were shown to contain PHGPx (Fig. 2 c). The predicted N-terminal (pos. 3-12) and C-terminal peptides (pos. 165-170), the fragment corresponding to positions 100-105 and those expected from the basic sequence part 119-151 were too small to be reliably identified. Interestingly, the fragment corresponding to positions 34-48 comprising the active site selenocysteine was not detected either. With these exceptions, however, the MALDI-TOF spectra unequivocally complied with the PHGPx sequence and thus proved the presence of PHGPx in spots 1-7. On a thicker 2D-gel developed with a non-linear gradient from pH 3-10 also five distinct spots were detected

in the 20 kDa region. In this experiments the presence of PHGPx was verified by microsequencing of major tryptic peptides (not shown). Again the spots representing PHGPx were the most prominent ones present in the gel.

5 The spots 1-6 of Fig. 2 a proved to be essentially homogeneous. As is exemplified in Fig. 2 b, the fragments yielding MALDI-TOF signals of significant intensities could be attributed to PHGPx. Only in the minor spot 7 a trace of impurity
10 was detected, which was tentatively identified as a subunit of the T cell receptor variable region (acc. no. 228109). Based on integrated stain intensities of the individual spots those representing PHGPx amounted to about 50% of the capsule material. Most of the minor components (see Fig. 2 a) are not
15 likely constituents of the capsule, which is believed to be built up by apposition of extramitochondrial proteins onto the outer mitochondrial membrane. In other gels further proteins like the mitochondrial glutathione S-transferase subunit Yb-2 (acc. no. 121719) and an endothelin converting enzyme (acc. no. 1706564) could be identified by MALDI-TOF or
20 micro-sequencing (not shown). Spots 8 and 9 were identified as the "outer dense fiber protein", a cystine-rich structural sperm protein, which is associated with the helix of mitochondria in the sperm midpiece but also extends into the *flagellum* (7). In view of the nature of the additional proteins
25 detected, the PHGPx content of the actual mitochondrial capsule should substantially exceed the 50% observed by gel scanning.

30 Despite intense search, we could not detect any trace of the "sperm mitochondria-associated cysteine-rich protein ("SMCP") (7) in our capsule preparation. This cysteine- and pro-

line-rich protein had for long been considered the selenoprotein accounting for the selenium content of the mitochondrial capsule in sperm (1,8,9). Cloning of the rat SMCP gene, however, revealed that it did not contain any in-frame TGA codon enabling selenocysteine incorporation (10). In mice, the three in-frame TGA codons proved to be upstream of the translation start (7). In developing mouse sperm SMCP stayed cytosolic up to states in which the mitochondrial capsule was already formed and only became superficially associated with the outer mitochondrial membranes of late spermatids and epididymal spermatozoa (7). SMCP thus is not necessarily an integral part of the mitochondrial capsule nor it is a selenoprotein. Instead, the "mitochondrial capsule selenoprotein (MCS)", as SMCP was originally referred to (1,7-10), is indeed PHGPx.

The chemical modifications of PHGPx leading to distinct differences in charge and apparent MW could not be reliably elucidated. Sequencing revealed an identical N-terminus of the size isomers starting with ASRDDWRCAR, i.e. a sequence either corresponding to the originally proposed translation start (11) after cleavage of the first two residues or derived from a possible pre-PHGPx (12) after processing of a mitochondrial leader peptide (13). Tryptic fragments extending towards the C-terminus up to position 164 were consistently observed also with the faster migrating specimen (Fig. 2 c) which leaves little room to explain an apparent MW difference of 1 to 1.5 kDa. As to the charge isomers, it may be recalled that a potential phosphorylation had been inferred from early attempts to sequence pig heart PHGPx (14). The assignment of masses to possibly phosphorylated tryptic peptides, however, remained equivocal. Certainly, more trivial events such as

00913361 " 120301
10E02119E2E660

deaminations of Gln and Asn residues, C-terminal degradation, oxidation of the active site selenium, or its elimination might have contributed to the charge heterogeneity.

PHGPx as the major component of the sperm mitochondrial capsule had so far escaped attention, since as such it is enzymatically inactive, as it generally is in mature spermatozoa prepared from the tail of the epididymis (Tab. 1). It is neither reactivated by glutathione in the low millimolar range as used under conventional test conditions. High concentrations of thiols (0.1 M 2-mercaptoethanol or dithiothreitol), which in the presence of guanidine fully dissolve the capsule, regenerate a significant PHGPx activity, as measured after elimination of denaturing and reducing agents (Tab. 1). In fact, the specific activities thus obtained from mitochondrial capsules exceed, by a factor of 20, the highest values ever measured, i.e. in spermatogenic cells. Nevertheless, this extreme PHGPx activity is still low compared to its content in PHGPx protein. Based on the specific activity of pure PHGPx, the reactivated enzyme would be equivalent to less than 3% of the capsule protein, whereas the 2D-electrophoresis suggests a PHGPx protein content of at least 50%. It is worth noting that the same reductive procedure does not increase the specific activity of PHGPx in spermatogenic cells from testicular tubules (Tab. 1). The switch of PHGPx from a soluble active enzyme to an enzymatically inactive structural protein thus occurs during final differentiation of spermatozoa.

The alternate roles of PHGPx, being either a glutathione-dependent hydroperoxide reductase or a structural protein, are not necessarily unrelated. One of the features common to

all glutathione peroxidases is a selenocysteine residue which together with a tryptophan and a glutamine residue forms a catalytic triad (15,16). Therein the selenol group of the selenocysteine residue is dissociated and highly activated by hydrogen bonding to reduce hydroperoxides with high rate constants. The reaction product, a selenenic acid derivative, R-SeOH, will readily react with thiols, e.g. GSH, to form an intermediate with a selenadisulfide bridge between enzyme and substrate, R-Se-S-G, from which the ground state enzyme can be regenerated by a second GSH. PHGPx is unique among the glutathione peroxidases in several respects: i) It usually is monomeric having its active site freely accessible at the surface; this facilitates interaction with bulky substrates. ii) Arginine residues surrounding the active site and specifically binding glutathione in most types of glutathione peroxidases are lacking in PHGPx (16); correspondingly, its specificity for the reducing substrate is less pronounced (16). It therefore can be envisaged that oxidized PHGPx may form diselenide or selenadisulfide bridges with exposed SeH or SH groups of proteins (16) including PHGPx itself, and this process, possibly followed by SH/SS, SH/SeS, or SH/SeSe exchange reactions, will create cross-linked protein aggregates. This ability of PHGPx might become particularly important if cells are exposed to hydroperoxides at extremely low concentration of glutathione, as is documented for late states of spermatogenesis (17-20). Fig. 3 is to mimic the oxidative events occurring during sperm maturation. Short term exposure of soluble proteins derived from spermatogenic cells to moderate H_2O_2 concentrations in the absence of GSH yields a variety of PHGPx-containing high molecular weight aggregates. Undoubtedly, therefore, PHGPx, by means of its intrinsic enzymatic potential, can catalyse oxidative protein

aggregation using protein thiols as alternate substrates. During sperm maturation, PHGPx thereby transforms itself into an enzymatically inactivated structural protein. This view, however, is not to imply that PHGPx could not depend on additional proteins when building up the highly organized architecture of the spermatozoal midpiece.

Our findings require a fundamental reconsideration of the role of selenium in male fertility. The intriguing predominance of the selenoprotein PHGPx in the male reproductive system has so far been believed to reflect the necessity to shield germ line cells from oxidative damage by hydroperoxides and reactive oxygen species derived therefrom (11,17,21,22). This concept still merits attention with regard to the mutagenic potential of hydroperoxides and probably holds true for the early phases of spermatogenesis where PHGPx is still present as an active peroxidase (6,21). At this stage related activities reported for PHGPx or other glutathione peroxidases, e.g. silencing lipoxxygenases (23), dampening the activation of NF B (24) or inhibiting apoptosis (25), may also be relevant. In later stages of spermatogenesis characterized by a shift of the redox status resulting in loss of GSH (18-20,26), the ability of PHGPx to use protein thiols as alternate substrates opens up new perspectives of redox regulation which remain to be explored. In the mature spermatozoon PHGPx has experienced a pronounced metamorphosis now being a major constituent of the keratinuous material embedding the mitochondrial helix. It appears revealing that precisely this architectural peculiarity in the midpiece of spermatozoa shows gross structural alterations in selenium deficiency. We therefore assume that the mechanical instability of the midpiece observed in selenium deficiency is a con-

sequence of an impaired PHGPx biosynthesis. This view implies that it is not the antioxidant capacity of PHGPx which is crucial for male fertility but its ability to utilize hydroperoxides to build an indispensable structural element of the spermatozoon.

Any shortage of PHGPx during sperm maturation, be it due to selenium deficiency, other reasons of inhibited biosynthesis or inhibition of activity should therefore result in disturbed sperm midpiece architecture and, in consequence, loss of fertilization potential of sperm. This conclusion was further corroborated by determination of reactivated PHGPx in sperm of individuals with documented fertility problems. The latter were divided into three groups: depending on whether i) intrauterine sperm injection (iui) or ii) conventional in-vitro-fertilisation (ivt-et) was still successful or iii) intracytoplasmatic sperm injection was required (icsi). As shown in Fig 4, the PHGPx values differed markedly between these groups. While the iui group displayed values close to normal, PHGPx in the icsi group was almost absent, the ivf-et group ranking in between. The reasons of the diverse PHGPx content being unknown, the data reveal that markedly reduced PHGPx content in sperm is incompatible with normal male fertility. Similarly, there is a strong correlation between "typical" sperm appearance (Fig 5) and "fast" moving sperm with PHGPx content (Fig 6). This correlation, however, shows marked scattering of data indicating that PHGPx content of sperm is not the only reason of abnormal shape and motility of sperm. It should also be pointed out that the sperm samples were taken from individuals without any obvious disease suggesting that extremely reduced PHGPx levels are well tolerated.

Taken together, the observation that PHGPx builds up an essential structure of sperm and that its content in sperm correlates with the fertilization potential leads to the inventive concept to use the PHGPx content of sperm as a predictive parameter for the necessary measures to overcome male fertility problems. To this end, it appears necessary to reactivate the PHGPx contained in sperm in order to estimate its content by either immunological methods or by any of the established determinations of its specific activity. (28, 29).

Methods

Preparation of rat spermatozoa, tubular cells and mitochondrial capsule

Spermatozoa of four month old Wistar rats (about 300 grams of body weight) were collected by squeezing *cauda epididymis* and *vas deferens* in phosphate buffer saline (PBS) and by centrifugating at 600 x g for 10 minutes. Cell and sperm pellets were layered on a discontinuous 45%, 70% and 95% Percoll gradient and centrifugated at 300 x g for 20 min. Spermatogenic cells stacked on top of the gradient, while spermatozoa separated into the 70% Percoll layer. Cells from seminiferous epithelium were prepared as follows (26): testes were deprived of *albuginea*, seminiferous tubules were cut into small pieces in PBS containing 0.250 mg/ml collagenase, and incubated twice 25 °C for 15 min. Cells then were filtered through a stainless steel screen (140 µm pore), washed in PBS and centrifugated at 300 x g for 10 min. Sperm mitochondrial capsule was prepared according to Calvin et al.(1): sperms were resuspended in 0.05 M Tris - HCl pH 8.0 at the concen-

tration of 10^6 cells/ml and treated with trypsin (0.2 mg/ml) for 10 minutes. After stopping the protease action with trypsin inhibitor (0.5 mg/ml) and SDS (10 mg/ml) sperms were centrifugated at $1,500 \times g$ for 10 minutes. Pellets were resuspended in 0.05 M Tris - HCl, pH 8.5 containing 1% sodium dodecyl sulphate (SDS), and 0.2 mM DTT and kept under continuous stirring for 30 minutes. Following centrifugation at $4,500 \times g$ for 15 min, the resulting supernatant was layered on a 1.6 M sucrose cushion. After centrifugation for 20 min at $18,000 \times g$ in a swinging rotor, sperm capsules were collected as a band at the top of the sucrose cushion, washed in Tris - HCl, pH 8.0 and spun at $140,000 \times g$.

1D-electrophoresis and Western blotting

Electrophoresis was performed according to Laemmli under either reducing (+ 2- mercaptoethanol) or non-reducing conditions. Proteins were blotted onto nitrocellulose, probed with an antigen-purified rabbit antibody raised against pig heart PHGPx and detected by biotinylated anti rabbit IgG and streptavidin alkaline phosphatase complex.

2D-electrophoresis

100 μ g of the mitochondrial capsule material was dissolved in 400 μ l of a solution containing of 7 M urea, 2 M thiourea, 4% CHAPS, 40 mM DTT, 20 mM Tris base and 0.5% IPG buffer (Pharmacia) and focused in an IPG-phor (Pharmacia) at 20°C by stepwise increasing voltage up to 5000 V but not exceeding a current of 30 μ A per IPG strip. The pH gradient was non-linear from 3-10 or linear from 3-10 or 6-11. The focussed IPG strips were then equilibrated for SDS electrophoresis (10 min each) with a solution containing 60 mM DTT in 6 M urea, 30% glycerol, 0.05 M Tris-HCl buffer pH 8.8 and in the same

buffer where DTT was substituted by 250 mM iodoacetamide. After SDS-electrophoresis (12% polyacrylamide) the gels were stained with Coomassie.

5 Protein identification

Coomassie-stained spots were cut out from the gels, neutralized with $(\text{NH}_4)\text{HCO}_3$, destained with 400 μl 50% acetonitrile/10 mM $(\text{NH}_4)\text{HCO}_3$ and dried in a Speed Vac Concentrator. Protein digestion was done overnight using 2 ng/ μl sequencing grade trypsin (Promega) in 50 mM $(\text{NH}_4)\text{HCO}_3$ (Boehringer, Mannheim). The resulting peptides were extracted twice with 60% acetonitrile / 40% H_2O / 0.1% TFA. Extracts were combined and lyophilized in the Speed Vac Concentrator. Peptide digests were desalted on small RP18-columns, eluted with saturated α -hydroxy-4-cyano-cinnamic acid and loaded directly onto the MALDI target (27). Reflectron MALDI mass spectra were recorded on a ReflexTM MALDI/TOF-mass spectrometer (Bruker-Franzen-Analytik, Bremen). The ions were accelerated at 20 kV and reflected at 21.3 kV. Spectra were externally calibrated using the monoisotopic MH^+ ion from two peptide standards. 100-200 laser shots were summed up for a single mass spectrum. Mass identification was performed with MS-Fit (<http://falcon.ludwig.ucl.ac.uk/ucshtml/msfit.htm>).

25 Alternatively, protein spots from 1.5 mm 2D-gels were digested with modified trypsin (Promega, sequencing grade) in 25 mM $(\text{NH}_4)\text{HCO}_3$ overnight at 37°C. The digests were extracted twice and dried as before and reconstituted in 10 μl water. Peptides were separated on a reversed-phase capillary column (0.5 mm x 150 mm) with a gradient of acetonitrile in 0.1% formic acid / 4 mM ammonium acetate at a flow rate of 5 $\mu\text{l}/\text{min}$ and collected manually. Aliquots of 5 μl were spotted onto

Biobrene-treated glass fiber filters and sequenced on an Applied Biosystems 494A sequencer with standard pulsed-liquid cycles. Before N-terminal sequencing, proteins were blotted from polyacrylamide gels onto PVDF membranes for 16 h at pH 8.3 (25 mM Tris-HCl, 192 mM glycine) and 100 mA (30 V).

When applicable, PHGPx was also identified by activity measurement according to (28) using the specific substrate phosphatidylcholine hydroperoxide.

Figure 1 Presence of PHGPx in the mitochondrial capsule of spermatozoa.

a, Mitochondrial capsule prepared by trypsinization and centrifugation according to (1) at 80,000 fold magnification. **b**, The same preparation as shown in **a**, but after exposure to 0.1 M 2-mercaptoethanol for 15 min at 4°C. Contamination of the capsule material by mitochondria is evident from the presence of mitochondrial ghosts. **c**, SDS gel electrophoresis of proteins extracted from capsule material (see Methods) by treatment with 0.1 M 2-mercaptoethanol, 0.1 M Tris-HCl, pH 7.5, and 8 M guanidine HCl. Left lane is stained with Coomassie, right lane demonstrates presence of PHGPx by Western blotting.

Figure 2 shows the analysis of the composition of the mitochondrial capsule of spermatozoa

a, 2D-electrophoresis of purified dissolved capsule material. Proteins were focused in a linear pH-gradient from 3 to 10 (horizontal direction), then reduced, amidocarboxymethylated, subjected to SDS-electrophoresis, and stained with Coomassie. MALDI-TOF analysis of the visible spots identified the following proteins (SwissProt data base): spot 1-7 PHGPx (MW 19

443; pI 8.27; acc. no. 544434); spots 8 and 9, outer dense fiber protein (MW 27351; pI 8.36; acc. no. P21769); spots 10 and 11, voltage-dependent anion channel-like protein (MW 31720; pI 7.44; acc. no. 540011); spot 12, "stress-activated protein kinase" (MW 48107; pI 5.65; acc. no. 493207); spot 13, glycerol-3-phosphate dehydrogenase (MW 76479; pI 5.86; acc. no. P35571).

b, MALDI-TOF spectrum (overview) of tryptic peptides obtained from PHGPx as found in spot 3. Abscissa, mass/charge ratio of the peptide fragments; ordinate, arbitrary units of intensity; numbers at mass signals, identified peptides in the PHGPx sequence (see insert for position numbers); T, trypsin-derived fragments.

c, Compilation of tryptic PHGPx fragments identified in spots 1-7 by MALDI-TOF. Vertical lines designate potential tryptic cleavage sites. Dark blocks, identified typical cleavage products; shadowed blocks, masses resulting from incomplete cleavage or equivocally assignable to different fragments (e.g. 3-9 and 63-69).

Figure 3 shows the formation of PHGPx-containing aggregates from spermatogenic cells by H_2O_2 in the absence of GSH. Spermatogenic cells were homogenised in 0.1 M Tris-HCl, 6 M guanidine-HCl, 0.5 μ g/ml pepstatin A, 0.7 μ g/ml leupeptin and 5mM 2-mercaptoethanol at pH 7.5 and 4°C. After centrifugation at 105,000 x g for 30 min, excess reagents were removed by gel permeation using NAP 5 columns equilibrated with 10mM Tris-HCl, 0.15 M NaCl, 1mM EDTA and 0.1% Triton X-100, pH 7.5. Immediately (t 0) and 15 min after (t 15) the addition of 75 μ M H_2O_2 aliquots of the mixture (0.05 mg of protein) were withdrawn and subjected to electrophoresis under (a) re-

ducing and (b) non reducing conditions. After blotting on nitrocellulose, PHGPx was detected by specific antibodies.

Figure 4 shows the PHGPx specific activity in extracts (0.1% Triton X-100 and 0.1 M 2-mercaptoethanol of human sperm. Correlation between this parameter and therapeutic approach in cases of couple infertility.

Figure 5 shows the relationship between PHGPx specific activity and number of "typical" sperms per milliliter of semen. "Typical" is a morphological parameter of sperm evaluation.

Figure 6 shows the relationship between PHGPx specific activity and number of "fast" sperms per milliliter of semen. "Fast" is a parameter of sperm mobility.

Table 1 PHGPx activity in spermatogenic cells, spermatozoa and sperm capsule. Effect of thiols.

Preparation	mU/mg protein ^{a, b}
Cells from seminiferous tubules	
5 mM 2-mercaptoethanol ^c	250 ± 10
100 mM 2-mercaptoethanol ^c	260 ± 10
Spermatozoa from tail of epididymis	
5 mM 2-mercaptoethanol ^c	undetectable
100 mM 2-mercaptoethanol ^c	3,140 ± 200
Mitochondrial capsule	
5 mM 2-mercaptoethanol ^c	undetectable
100 mM 2-mercaptoethanol ^c	5,600 ± 290

^a One enzyme mU catalyzes the reduction of one nanomole of phosphatidylcholine hydroperoxide per minute at 37 °C in the presence of 3 mM GSH.

5 ^b Data are the mean and S. D. of five independent measurements.

10 ^c Solubilisation / reduction was carried out in 0.1 M Tris-HCl, 6 M guanidine-HCl, 0.5 µg/ ml pepstatin A, 0.7 µg/ml leupeptin and 2-mercaptoethanol as indicated at pH 7.5 and 4 °C for 10 min Low molecular weight compounds were removed before activity determination by a NAP 5 cartridge.

00913364 130304
10021 " 130304

References

1. Calvin, H. I., Cooper, G. W. & Wallace, E. Evidence that selenium in rat sperm is associated with a cysteine-rich structural protein of the mitochondrial capsules. *Gamete Res.* 4, 139-149 (1981).
2. Brown, D.G. & Burk, R.F. Selenium retention in tissues and sperm of rats fed a *Torula* yeast diet. *J. Nutr.* 103, 102-108 (1973).
3. Wu, A.S.H., Oldfield, J.E., Shull, L.R. & Cheeke, P.R. Specific effect of selenium deficiency on rat sperm. *Biol. Reprod.* 20, 793-798 (1979).
4. Wallace, E., Calvin, H.I., Ploetz, K. & Cooper, G.-W. Functional and developmental studies on the role of selenium in spermatogenesis. In: Combs, G.F., Levander, O.A., Spallholz, J.E., and Oldfield, J.E. (eds): *Selenium in Biology and Medicine*. AVI Publishing Co, Westport, CT Part A, 181-196 (1987).
5. Behne, D., Weiler, H. & Kyriakopoulos, A. Effects of selenium deficiency on testicular morphology and function in rats. *J. Reprod. Fertil.* 106, 291-297 (1996).
6. Maiorino, M. et al. Testosterone mediates expression of the selenoprotein PHGPx by induction of spermatogenesis and not by direct transcriptional gene activation. *FASEB J.* 12, 1359-1370 (1998).
7. Cataldo, L., Baig, K., Oko, R., Mastrangelo, M.-A. & Kleene, K.C. Developmental expression, intracellular localization, and selenium content of the cysteine-rich protein associated with the mitochondrial capsules of mouse sperm. *Mol. Reprod. Dev.* 45, 320-331 (1996).

8. Pallini, V. & Bacci, E. Bull sperm selenium is bound to a structural protein of mitochondria. *J. Submicr. Cytol.* 11, 165-170 (1979).
9. Nam, S.-Y., Youn, H.-Y., Ogawa, K., Kurohmaru, M. & Hayashi, Y. Expression of mitochondrial capsule selenoprotein mRNA increases with aging, but decreases by selenium deficiency in the mouse testis. *J. Reprod. Develop.* 43, 227-234 (1997).
10. Adham, I.M. et al. Cloning, expression, and chromosomal localization of the rat mitochondrial capsule selenoprotein gene (MCS): the reading frame does not contain potential UGA selenocysteine codons. *DNA Cell Biol.* 15, 159-166 (1996).
11. Brigelius-Flohé, R. et al. Phospholipid-hydroperoxide glutathione peroxidase: genomic DNA, cDNA, and deduced amino acid sequence. *J. Biol. Chem.* 269, 7342-7348 (1994).
12. Pushpa-Rekha, T.R., Burdsall, A.L., Oleksa, L.M., Chisolm, G.M. & Driscoll, D.M. Rat phospholipid-hydroperoxide glutathione peroxidase. cDNA cloning and identification of multiple transcription and translation start sites. *J. Biol. Chem.* 270, 26993-26999 (1995).
13. Arai, M. et al. Import into mitochondria of phospholipid hydroperoxide glutathione peroxidase requires a leader sequence. *Biochem. Biophys. Res. Comm.* 227, 433-439 (1996).
14. Schuckelt, R. et al. Phospholipid hydroperoxidase glutathione peroxidase is a selenoenzyme distinct from the classical glutathione peroxidase as evident from cDNA and amino acid sequencing. *Free Rad. Res. Comm.* 14, 343-361 (1991).
15. Maiorino, M. et al. Probing the presumed catalytic triad of selenium-containing peroxidases by mutational analysis of phospholipid hydroperoxide glutathione peroxidase (PHGPx). *Biol. Chem. Hoppe Seyler* 376, 651-660 (1995).

- 30

25. Sandstrom, P.A., Murray, J., Folks, T.M. & Diamond, A.M. Antioxidant defenses influence HIV-1 replication and associated cytopathic effects. *Free Radic. Biol. Med.* **24**, 1485-1491 (1998).
- 5 26. Li, L., Seddon, A.P., Meister, A. & Risley, M. S.. Spermatogenic cell - somatic cell interaction are required for maintenance of spermatogenic cell glutathione. *Biol. Reprod.* **40**, 317-331 (1989).
- 10 27. Gobom, J., Nordhoff, E., Ekman, R., Roepstorff, P. Rapid micro-scale proteolysis of proteins for MALDI-MS peptide mapping using immobilized trypsin. *Int. J. Mass Spectrom.* **169/170**, 153-163 (1998).
- 15 28. Roveri, A., Maiorino, M. & Ursini, F. Enzymatic and immunological measurements of soluble and membrane bound PHGPx. *Meth. Enzymol.* **233**, 202- 212 (1994).
29. Flohé, L. Determination of glutathione peroxidase. In: CRC Handbook of Free radicals and Antioxidants in Biomedicine, Vol. III. J. Miquel, A.T. Quintanilha and H. Weber (eds.). CRC Press, Inc., Boca Raton/Florida, 281-286 (1988).
- 20 30. Brecht, A., Rothmund, M., Schütz, A., Schabel, U. Gauglitz, G. Optische Methoden im High-Throughoutput-Screening zur Wirkstoffsuche. *BioTec* **3**, 26-28 (1998).

Claims


1. Method for the determination of latent phospholipid hydroperoxide glutathione peroxidase (PHGPx) comprising the steps of
 - a) obtaining a sperm sample,
 - b) solubilizing the spermatozoa by using detergents and chaotropic agents and reactivating latent PHGPx by using high concentrations of thiols and
 - c) determining enzymatic activity of reactivated latent PHGPx.
2. Method according to claim 1, wherein between said step of solubilizing the spermatozoa and said step of determining the enzymatic activity of reactivated latent PHGPx an additional step of removing any reactivating reagents is provided.
3. Method according to claim 2, wherein said additional step of removing any reactivating reagents is performed by gel filtration.
4. Method according to any of the preceeding claims, wherein instead of determining enzymatic activity of reactivated latent PHGPx the content of solubilized PHGPx is determined by conventional immunological techniques or measurement of enzymatic activity.
5. Method according to any of the preceeding claims, wherein the chaotropic agent is 4 - 8 M guanidine chloride, 4 - 8 M guanidine thiocyanate or 5 - 8 M urea.

6. Method according to any of the preceeding claims, wherein the thiol is 50 - 300 mM 2-mercaptoethanol, 25 - 300 mM dithiothreitol (DTT) or dithioerythritol (DTE).
 - 5 7. Method according to any of the preceeding claims, wherein the sperm sample is from humans or life stock.
 8. Use of a method of any of the preceeding claims in a method for predicting the fertilizing potential of spermatozoa in sperm samples.
- 10

00943364-120304

5

FIG.1



Mass spectrum of the pyrolysate of poly(2-vinylpyridine) showing relative intensity (a.i.) versus m/z . The spectrum displays several prominent peaks labeled 1 through 17. The corresponding m/z values for these peaks are listed on the right side of the plot.

Peak Number	m/z Values	Identification
1=	63 - 69	
2=	13 - 20	
3=	6 - 12	
4=	91 - 99	
5=	141 - 151	
6=	70 - 80	
7=	153 - 164	
8=	153 - 164	(Met-ox)
9=	106 - 118	
10=	152 - 164	
11=	152 - 164	(Met-ox)
12=	21 - 33	
13=	49 - 62	
14=	91 - 105	
15=	81 - 99	(pyro-Glu)
16=	81 - 99	
17=	70 - 90	

spot	amino acid residues 3-170																																																																					
1																																																																						
2																																																																						
3																																																																						
4																																																																						
5																																																																						
6																																																																						
7																																																																						

Fig. 3





Fig. 4



4 / 4

Fig. 5





Fig. 6



12166

Please type a plus sign (+) inside this box. →

Approved for use through 9/30/00. OMB 0851-0032
 Patents and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Persons are required to respond to a collection of information unless it contains
 a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains
 a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input type="checkbox"/> Declaration Submitted with Initial Filing OR <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	Attorney Docket Number	227-144 930008-2005
	First Named Inventor	Leopold Flohe
	COMPLETE IF KNOWN	
	Application Number	09/913,361
	Filing Date	
	Group Art Unit	
	Examiner Name	

As a below named inventor, I hereby declare

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"Method to Detect Male Antifertility Problems"

the specification of which (Title of the Invention)

☐ is attached hereto OR ☒ was filed on (MM/DD/YYYY) 03/06/2000 as United States Application Number or PCT International Application Number PCT/EP00/01877 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(c)-(d) or 365(e) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?
EP 99 103 959.5	Europe	03/09/1999	<input type="checkbox"/>	<input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under 35 U.S.C. 115(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

☐ Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

(Page 1 of 3)

Burdon Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12/87)
Approved for use through 9/30/90, OMB 065-0022
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION—Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U. S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (If applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to conduct all business in the Patent and Trademark Office connected therewith:

<input type="checkbox"/> Customer Number	<input type="checkbox"/> Place Customer Number Bar Code Label here
<input checked="" type="checkbox"/> Registered practitioner(s) name/registration number listed below	
Name	Registration Number
Ronald R. Santucci	28,988

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label ☒ Correspondence address below

Name	Ronald R. Santucci				
Address	Pitney, Hardin, Kipp & Szuch LLP				
Address	711 Third Avenue, 20th Floor				
City	New York	State	NY	ZIP	10017
Country	U.S.A.	Telephone	212-687-6000	Fax	212-682-3485

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that those statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:	<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle (if any))	Family Name or Surname				
Leopold	Flohe				
Inventor's Signature	<i>Leopold Flohe</i>			Date	12.09.91
Residence: City	Braunschweig	State	Country	Germany	Citizenship
Post Office Address	Mascheroder Weg 1,				
Post Office Address	D-38124 Braunschweig, Germany				
City		State	ZIP		Country

☒ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-87)
Approved for use through 9/30/96. OMB 0551-0022
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

DECLARATION	ADDITIONAL INVENTOR(S) Supplemental Sheet Page <u>2</u> of <u>2</u>
--------------------	---

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
<u>Fulvio</u>		<u>Ursini</u>	
Inventor's Signature	<u>Fulvio Ursini</u>		Date <u>09/10/01</u>
Residence: City	<u>Braunschweig</u>	State	Country <u>Germany DEX</u> Citizenship <u>Italian</u>
Post Office Address <u>Mascheroder Weg 1.</u>			
Post Office Address <u>D-38124 Braunschweig, Germany</u>			
City		State	ZIP Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
<u>Antonella</u>		<u>Roveri</u>	
Inventor's Signature	<u>Antonella Roveri</u>		Date <u>09/10/01</u>
Residence: City	<u>Braunschweig</u>	State	Country <u>Germany DEX</u> Citizenship <u>Italian</u>
Post Office Address <u>Mascheroder Weg 1.</u>			
Post Office Address <u>D-38124 Braunschweig, Germany</u>			
City		State	ZIP Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Inventor's Signature			Date
Residence: City		State	Country Citizenship
Post Office Address			
Post Office Address			
City		State	ZIP Country

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


+

09013361 1203001

2-06
X

3-00

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

X Scanned copy is best available. Drawing figure #1
is dark.